Safety study
Showing 1 - 25 of >10,000
Kesimpta Pregnancy and Infant Safety Study Using Real World Data
Not yet recruiting
- Multiple Sclerosis
- Multiple sclerosis disease modifying drug
- (no location specified)
Nov 27, 2023
Native Estrogen Estetrol (E4) Safety Study
Recruiting
- Contraception
- Birth Control
-
Berlin, GermanyBerlin Center for Epidemiology and Health Research
Aug 31, 2023
Presbyopia, Near Vision, Miosis Trial in Chandler, Glendale (Aceclidine+Brimonidine combination ophthalmic solution, Placebo,
Recruiting
- Presbyopia
- +3 more
- Aceclidine+Brimonidine combination ophthalmic solution
- +2 more
-
Chandler, Arizona
- +1 more
Mar 2, 2023
BrazilianDiagnosis of Spinal Muscular Atrophy Treated With
Not yet recruiting
- Spinal Muscular Atrophies
- Onasemnogene Abeparvovec
- (no location specified)
Aug 25, 2023
Scabies Trial (Moxidectin Oral Product, Placebo)
Not yet recruiting
- Scabies
- Moxidectin Oral Product
- Placebo
- (no location specified)
May 28, 2023
A Prospective, Non-interventional, Long-term, Post-Authorisation
Not yet recruiting
- Growth Hormone Deficiency
- No intervention
- (no location specified)
Mar 8, 2023
Sarcoma, Soft Tissue Trial in Changsha (Cardunilizumab)
Active, not recruiting
- Sarcoma, Soft Tissue
-
Changsha, Hunan, ChinaXiangya Hospital Central South University
Oct 29, 2023
Neuromyelitis Optica Spectrum Disorder Exposed to UPLIZNA®
Not yet recruiting
- Neuromyelitis Optica Spectrum Disorder
- Pregnancy Related
- (no location specified)
Jun 9, 2023
Growth Hormone Deficiency Trial in Centennial (No intervention)
Recruiting
- Growth Hormone Deficiency
- No intervention
-
Centennial, ColoradoAscendis Pharma Investigational Site
Apr 18, 2023
Coronary Artery Disease Trial (LiquID GCE Use)
Recruiting
- Coronary Artery Disease
- LiquID GCE Use
-
Genk, BelgiumZiekenhuis Oost-Limburg
Oct 24, 2022
Opioid Withdrawal (Disorder) Trial (Standard of Care with Lofexidine, Standard of Care without Lofexidine)
Not yet recruiting
- Opioid Withdrawal (Disorder)
- Standard of Care with Lofexidine
- Standard of Care without Lofexidine
- (no location specified)
Sep 14, 2023
Essential Tremor Trial (60 mg ulixacaltamide, Placebo)
Not yet recruiting
- Essential Tremor
- 60 mg ulixacaltamide
- Placebo
- (no location specified)
Oct 12, 2023
Moderate to Severe Asthma Trial (povorcitinib, , ICS-LABA)
Not yet recruiting
- Moderate to Severe Asthma
- povorcitinib
- +2 more
- (no location specified)
May 9, 2023
Schizophrenia Trial in Catonsville (Clozapine)
Completed
- Schizophrenia
-
Catonsville, MarylandMaryland Psychiatric Research Center
Jan 11, 2023
Study to Evaluate the Risk of Cardiovascular Endpoints
Completed
- Pulmonary Disease, Chronic Obstructive
- Aclidinium bromide
- Other COPD medication
-
London, United KingdomClinical Practice Research Datalink
Jan 30, 2023
Bacterial Infections Trial (Xeruborbactam Oral Prodrug, Ceftibuten, Xeruborbactam Oral Prodrug Placebo)
Not yet recruiting
- Bacterial Infections
- Xeruborbactam Oral Prodrug
- +3 more
- (no location specified)
Oct 6, 2023
A Safety Study on Posterior Pedicle Screw System
Recruiting
- Degenerative Disc Disease
- +2 more
- MUST MINI system
-
München, GermanyMünchen Klinik Bogenhausen
Apr 18, 2023
Safety Study of Fenofibrate During Pregnancy
Recruiting
- Severe Hypertriglyceridemia During Pregnancy
-
Hangzhou, Zhejiang, ChinaHangzhou First People's Hospital
May 31, 2023
Effectiveness of a Real Time Data Safety Study Tool
Completed
- Study Subjects Currently Enrolled in a Clinical Research Trial
-
Scottsdale, ArizonaPerseverance Research Center, LLC
Nov 14, 2022
CTX0E03 in Subjects Who Completed PISCES III Phase 2b Study
Enrolling by invitation
- Ischemic Stroke
- Non Interventional long term safety follow up
-
Morgantown, West VirginiaAmy Miller, RPh, PharmD
Oct 25, 2022
Neovascular Age-related Macular Degeneration (NVAMD), Diabetic Macular Edema (DME) Trial in United States (EYE103)
Recruiting
- Neovascular Age-related Macular Degeneration (NVAMD)
- Diabetic Macular Edema (DME)
-
Phoenix, Arizona
- +4 more
Jun 14, 2023